JP2004522803A - インターフェロン製剤 - Google Patents

インターフェロン製剤 Download PDF

Info

Publication number
JP2004522803A
JP2004522803A JP2003508390A JP2003508390A JP2004522803A JP 2004522803 A JP2004522803 A JP 2004522803A JP 2003508390 A JP2003508390 A JP 2003508390A JP 2003508390 A JP2003508390 A JP 2003508390A JP 2004522803 A JP2004522803 A JP 2004522803A
Authority
JP
Japan
Prior art keywords
interferon
polypeptide
composition
composition according
interferon gamma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003508390A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004522803A5 (enExample
Inventor
イェーン・ドルストルップ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxygen Holdings Ltd
Original Assignee
Maxygen Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Holdings Ltd filed Critical Maxygen Holdings Ltd
Publication of JP2004522803A publication Critical patent/JP2004522803A/ja
Publication of JP2004522803A5 publication Critical patent/JP2004522803A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2003508390A 2001-06-29 2002-06-28 インターフェロン製剤 Withdrawn JP2004522803A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200101040 2001-06-29
DKPA200101277 2001-08-30
DKPA200200257 2002-02-19
PCT/DK2002/000444 WO2003002152A2 (en) 2001-06-29 2002-06-28 Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins

Publications (2)

Publication Number Publication Date
JP2004522803A true JP2004522803A (ja) 2004-07-29
JP2004522803A5 JP2004522803A5 (enExample) 2006-01-05

Family

ID=27222516

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003508390A Withdrawn JP2004522803A (ja) 2001-06-29 2002-06-28 インターフェロン製剤

Country Status (7)

Country Link
EP (1) EP1414498A2 (enExample)
JP (1) JP2004522803A (enExample)
CN (1) CN1522159A (enExample)
CA (1) CA2452364A1 (enExample)
MX (1) MXPA03011793A (enExample)
RU (1) RU2004102500A (enExample)
WO (1) WO2003002152A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008069073A (ja) * 2006-09-12 2008-03-27 Yokohama Tlo Co Ltd ラクトフェリン複合体及びその製造方法
JP2009505645A (ja) * 2005-08-26 2009-02-12 アレス トレーディング ソシエテ アノニム グリコシル化されたインターフェロンベータの調製方法
JP2009529027A (ja) * 2006-03-08 2009-08-13 ビオメトード ヒトインターフェロンガンマ（ＩＦＮγ）変異体
JP2011506562A (ja) * 2007-12-20 2011-03-03 メルク セローノ ソシエテ アノニム Ｐｅｇインターフェロン−ベータ製剤
JP2012509269A (ja) * 2008-11-17 2012-04-19 ジェネンテック， インコーポレイテッド 生理的条件下での高分子の凝集を低減するための方法及び製剤
US10525137B2 (en) 2015-12-30 2020-01-07 Genentech, Inc. Formulations with reduced degradation of polysorbate
JP2024137947A (ja) * 2018-07-30 2024-10-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターフェロン－ガンマバイアス型アゴニスト

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7959910B2 (en) 2000-07-31 2011-06-14 Biolex Therapeutics, Inc. C-terminally truncated interferon alpha variants
AU2003254641A1 (en) * 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
US20040126360A1 (en) * 2002-10-09 2004-07-01 Manning Mark C. Oral formulations for proteins and polypeptides
RS20050502A (sr) 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polimerni konjugati interferona- beta sa povećanom biološkom aktivnošću
US7846427B2 (en) 2003-12-11 2010-12-07 Ares Trading S.A. Stabilized interferon liquid formulations
BRPI0510527A (pt) * 2004-06-01 2007-10-30 Ares Trading Sa método de estabilização de proteìnas
US20070212306A1 (en) * 2004-06-07 2007-09-13 Quay Steven C Intranasal formulations of interferon beta free of stabilizers that are proteins or polypeptides
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
US20070243163A1 (en) * 2006-02-17 2007-10-18 Chih-Ping Liu Respiratory tract delivery of interferon-tau
EP2102355B1 (en) 2006-12-14 2016-03-02 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same
MX2009011619A (es) * 2007-04-27 2010-01-18 Cydex Pharmaceuticals Inc Formulaciones que contienen clopidogrel y eter sulfoalquilico-ciclodextrina y metodos de uso.
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
KR101743591B1 (ko) 2009-05-13 2017-06-20 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
RU2482871C2 (ru) * 2010-06-07 2013-05-27 Общество с ограниченной ответственностью "Центр Инновационных Технологий "БиоФарм" (ООО "ЦИТ "БиоФарм") Композиция для лечения вирусных заболеваний животных
SE1450130A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
US10012064B2 (en) 2015-04-09 2018-07-03 Highlands Natural Resources, Plc Gas diverter for well and reservoir stimulation
US10344204B2 (en) 2015-04-09 2019-07-09 Diversion Technologies, LLC Gas diverter for well and reservoir stimulation
US10982520B2 (en) 2016-04-27 2021-04-20 Highland Natural Resources, PLC Gas diverter for well and reservoir stimulation
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
JP7105200B2 (ja) * 2016-05-13 2022-07-22 オリオニス バイオサイエンシズ ビーブイ 標的突然変異体インターフェロン－ベータおよびその使用
CN111358938B (zh) * 2020-03-30 2023-08-11 温州肯恩大学(Wenzhou-KeanUniversity) 人干扰素-ε与干扰素-γ组合药及用途
CN113797317B (zh) * 2021-10-26 2024-01-09 科兴生物制药股份有限公司 一种组合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6133248A (en) * 1997-06-13 2000-10-17 Cydex, Inc. Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009505645A (ja) * 2005-08-26 2009-02-12 アレス トレーディング ソシエテ アノニム グリコシル化されたインターフェロンベータの調製方法
JP2009529027A (ja) * 2006-03-08 2009-08-13 ビオメトード ヒトインターフェロンガンマ（ＩＦＮγ）変異体
JP2008069073A (ja) * 2006-09-12 2008-03-27 Yokohama Tlo Co Ltd ラクトフェリン複合体及びその製造方法
JP2011506562A (ja) * 2007-12-20 2011-03-03 メルク セローノ ソシエテ アノニム Ｐｅｇインターフェロン−ベータ製剤
JP2014159445A (ja) * 2007-12-20 2014-09-04 Merck Serono Sa Ｐｅｇインターフェロン−ベータ製剤
JP2012509269A (ja) * 2008-11-17 2012-04-19 ジェネンテック， インコーポレイテッド 生理的条件下での高分子の凝集を低減するための方法及び製剤
US10525137B2 (en) 2015-12-30 2020-01-07 Genentech, Inc. Formulations with reduced degradation of polysorbate
US10933141B2 (en) 2015-12-30 2021-03-02 Genentech, Inc. Formulations with reduced degradation of polysorbate
JP2024137947A (ja) * 2018-07-30 2024-10-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターフェロン－ガンマバイアス型アゴニスト
US12410226B2 (en) 2018-07-30 2025-09-09 The Board Of Trustees Of The Leland Stanford Junior University Interferon-gamma biased agonists

Also Published As

Publication number Publication date
EP1414498A2 (en) 2004-05-06
CN1522159A (zh) 2004-08-18
MXPA03011793A (es) 2004-04-02
RU2004102500A (ru) 2005-04-10
CA2452364A1 (en) 2003-01-09
WO2003002152A3 (en) 2003-05-01
WO2003002152A2 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
JP2004522803A (ja) インターフェロン製剤
US20030138403A1 (en) Interferon formulations
EP1366075B1 (en) New interferon beta-like molecules
US7338788B2 (en) Interferon-β variants and conjugates
US7144574B2 (en) Interferon β variants and conjugates
US20090030183A1 (en) Interferon Beta-Like Molecules
KR20020065517A (ko) 인터페론 감마 접합체
JP2003527090A (ja) 新規なインターフェロンベータ様分子
WO2002036626A1 (en) Single-chain multimeric polypeptides
JP2005518183A (ja) インターフェロンガンマポリペプチド変異体
US20060083715A1 (en) Interferon beta-like molecules for treatment of stroke
US7524931B2 (en) Full-length interferon gamma polypeptide variants
US7390638B2 (en) S99T C-11 Truncated polynucleotides encoding interferon gamma polypeptide variants
US20020169290A1 (en) New multimeric interferon beta polypeptides
RU2268749C2 (ru) КОНЪЮГАТЫ γ-ИНТЕРФЕРОНА
WO2002036628A2 (en) New multimeric interferon beta polypeptides
AU2002319109A1 (en) Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins
ZA200303964B (en) New interferon beta-like molecules.
AU2002235727A1 (en) New interferon beta-like molecules
ZA200200337B (en) New interferon beta-like molecules.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050601

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20060213